| Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial DJ Serisier, D Bilton, A De Soyza, PJ Thompson, J Kolbe, HW Greville, ... Thorax 68 (9), 812-817, 2013 | 285 | 2013 |
| Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system P Chattopadhyay, BY Shekunov, D Yim, D Cipolla, B Boyd, S Farr Advanced drug delivery reviews 59 (6), 444-453, 2007 | 284 | 2007 |
| Development of liposomal ciprofloxacin to treat lung infections D Cipolla, J Blanchard, I Gonda Pharmaceutics 8 (1), 6, 2016 | 203 | 2016 |
| Liposomal formulations for inhalation D Cipolla, I Gonda, HK Chan Therapeutic delivery 4 (8), 1047-1072, 2013 | 180 | 2013 |
| Assessment of aerosol delivery systems for recombinant human deoxyribonuclease DC Cipolla, AR Clark, HK Chan, I Gonda, SJ Shire STP Pharma Sciences 4 (1), 50-62, 1994 | 147 | 1994 |
| Lipid-based carriers for pulmonary products: preclinical development and case studies in humans D Cipolla, B Shekunov, J Blanchard, A Hickey Advanced drug delivery reviews 75, 53-80, 2014 | 130 | 2014 |
| Pulmonary formulations: what remains to be done? JG Weers, J Bell, HK Chan, D Cipolla, C Dunbar, AJ Hickey, IJ Smith Journal of Aerosol Medicine and Pulmonary Drug Delivery 23 (S2), S-5-S-23, 2010 | 129 | 2010 |
| Drug nanocrystallisation within liposomes T Li, D Cipolla, T Rades, BJ Boyd Journal of Controlled Release 288, 96-110, 2018 | 118 | 2018 |
| Physical stability of dry powder inhaler formulations N Shetty, D Cipolla, H Park, QT Zhou Expert opinion on drug delivery 17 (1), 77-96, 2020 | 111 | 2020 |
| Characterization of aerosols of human recombinant deoxyribonuclease I (rhDNase) generated by jet nebulizers D Cipolla, I Gonda, SJ Shire Pharmaceutical research 11, 491-498, 1994 | 102 | 1994 |
| Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia HX Ong, D Traini, D Cipolla, I Gonda, M Bebawy, H Agus, PM Young Pharmaceutical research 29, 3335-3346, 2012 | 91 | 2012 |
| Development and characterization of an in vitro release assay for liposomal ciprofloxacin for inhalation D Cipolla, H Wu, S Eastman, T Redelmeier, I Gonda, HK Chan Journal of pharmaceutical sciences 103 (1), 314-327, 2014 | 85 | 2014 |
| Prefilter for prevention of clogging of a nozzle in the generation of an aerosol and prevention of administration of undesirable particles R Rubsamen, I Gonda, S Farr, D Cipolla US Patent 5,829,435, 1998 | 78 | 1998 |
| Minimizing variability of cascade impaction measurements in inhalers and nebulizers M Bonam, D Christopher, D Cipolla, B Donovan, D Goodwin, S Holmes, ... Aaps Pharmscitech 9, 404-413, 2008 | 73 | 2008 |
| Dual action, inhaled formulations providing both an immediate and sustained release profile DC Cipolla, J Blanchard US Patent 8,071,127, 2011 | 72 | 2011 |
| Formulation technology to repurpose drugs for inhalation delivery DC Cipolla, I Gonda Drug Discovery Today: Therapeutic Strategies 8 (3-4), 123-130, 2011 | 72 | 2011 |
| Inhaled liposomal ciprofloxacin: once a day management of respiratory infections P Bruinenberg, JD Blanchard, DC Cipolla, F Dayton, S Mudumba, ... Respiratory drug delivery 1, 73-82, 2010 | 72 | 2010 |
| Modifying the release properties of liposomes toward personalized medicine D Cipolla, H Wu, I Gonda, S Eastman, T Redelmeier, HK Chan Journal of pharmaceutical sciences 103 (6), 1851-1862, 2014 | 66 | 2014 |
| In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation HX Ong, F Benaouda, D Traini, D Cipolla, I Gonda, M Bebawy, B Forbes, ... European Journal of Pharmaceutics and Biopharmaceutics 86 (1), 83-89, 2014 | 62 | 2014 |
| Dual action, inhaled formulations providing both an immediate and sustained release profile DC Cipolla, J Blanchard US Patent 8,268,347, 2012 | 60 | 2012 |
hakkim chanProfessor in Pharmaceutics, University of SydneyVerified email at sydney.edu.au
